Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Shinichi Imamura

Takaharu Hirayama

Takuto Kojima

Yoshiteru Ito

Noriyuki Nii

Youichi Kawakita

Yusuke Tominari

Koji Ono

Hiroshi Banno

Yasuhiro Hirata

Naoki Miyamoto

Naoki Iwamura

Daisuke Tomita

Masanori Baba

Xin Liu

Naoyuki Kanzaki

Osamu Nishimura

Keisuke Imamura

Nobuki Sakauchi

Shohei Hashiguchi

Osamu Kurasawa

Nozomu Sakai

Naoki Tomita

Satoru Matsuda

Shigemitsu Matsumoto

Yasutomi Asano

Terufumi Takagi

Tzu-Tshin Wong

Shuji Kitamura

Yasufumi Miyamoto

Yusuke Sasaki

Masanori Okaniwa

Yuta Tanaka

Douglas Robert Cary

Moriteru Asano

Yoshihiro Sugihara

Kazuko Yonemori

Bunnai Saito

Shigeo Kajii

Ken Tsuchida

Ryujiro Hara

Yukio Ishibashi

Takashi Ichikawa

Ryosuke Arai

Osamu Sano

Taeko Hattori

Yasushi Hattori

Toshio Tanaka

Masato Yoshida

Hidekazu Tokuhara

Masashi Toyofuku

Yuya Oguro

Tomohiro Kaku

Yasuyoshi Arikawa

Kazuhiro Miwa

Atsushi Hasuoka

Mitsuhiro Ito

Tetsuo Miwa

Shinji Morimoto

Taisuke Katoh

Katsunori Nagai

Masao Hirakata

Arai Ryosuke

Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

Heterocyclic compound

Provided is a compound represented by the following formula, or a salt thereof: 

Fused heterocyclic compound

Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].

Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic amide compound

Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.

The present invention relates to N-((3S,4R)-1-((8-chloroquinoxalin-6-yl)carbonyl)-3-(4-fluorophenyl)piperidin-4-yl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide, which is a compound that can be useful for the treatment or prevention of SPT-related diseases including congenital diseases associated with the storage of sphingolipids, such as cancer and Niemann-Pick disease, or a salt thereof.

The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s);

Cyclopropanamine compound and use thereof

The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group or heterocyclic group optionally having substituent(s); R is H, a hydrocarbon group or heterocyclic group optionally having substituent(s); A and R are optionally bonded to each other to form a ring optionally having substituent(s); Q, Q, Qand Qare each a hydrogen atom or a substituent; Qand Q, and Qand Q, are each optionally bonded to each other to form a ring optionally having substituent(s); X is H, an acyclic hydrocarbon group or saturated cyclic group optionally having substituent(s); Y, Yand Yare each H, a hydrocarbon group or heterocyclic group optionally having substituent(s); X and Y, and Yand Y, are each optionally bonded to each other to form a ring optionally having substituent(s); and Z, Zand Zare each H or a substituent, or a salt thereof.

Cyclopropaneamine compound

The present invention provides a novel compound having a superior activity as an ERR-&#x3b1; modulator and useful as an agent for the prophylaxis or treatment of ERR-&#x3b1; associated diseases. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Nitrogen-containing heterocyclic compound

Growing community of inventors

Kanagawa, Japan

Shinichi Imamura